spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  CRESTOR 

 HSMN NewsFeed - 27 May 2021
Betagenon AB announces new CEO and new Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2018
Roivant Expands Senior Leadership with Key Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Mar 2017
Tris Pharma Appoints New Chief Commercial Officer for Brand Business
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 17 Jan 2017
Personal Genome Diagnostics Adds James Lewis as Senior Vice President of Corporate Development
Diagnostics Oncology Personalized Medicine Personnel
 HSMN NewsFeed - 3 Aug 2016
Allergan Announces Sale of Anda Distribution Business to Teva Pharmaceutical
Biopharmaceuticals Distribution Acquisitions
 HSMN NewsFeed - 20 Jul 2016
Mylan Launches Generic Crestor(R) Tablets
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 2 May 2016
Allergan Receives FDA Approval and Launches First Generic Version of CRESTOR(R) (rosuvastatin)
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 13 Aug 2015
Innocoll AG Appoints Rich Fante as Chief Commercial Officer and Head of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2014
Mylan Appoints Adele Gulfo as EVP, Global Collaboration and Strategic Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jun 2012
EMD Serono, Inc. Strengthens Leadership Teams with New Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2011
Shionogi Announces New US Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jul 2010
Shionogi Inc. Announces FDA Approval of CUVPOSA for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 1 Jul 2010
Shionogi Announces Reorganization of US Operations, New Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2010
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra(R) (lopinavir / ritonavir) for Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 27 Apr 2010
CRESTOR(TM) Gains New EU Indication to Prevent Major Cardiovascular Events in High Risk Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 21 Jan 2010
Shionogi Pharma Appoints Ray Russo as Vice President, Primary Care Business Unit
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jul 2009
Sciele Pharma and Plethora Solutions Announce Positive Results of Final Phase III Pivotal Trial for PSD502 for Premature Ejaculation
Biopharmaceuticals
 HSMN NewsFeed - 10 Jul 2009
Sciele Pharma, a Shionogi Company, Terminates Agreement to Acquire Victory Pharma, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 4 Jun 2009
Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2009
Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
Biopharmaceuticals
 HSMN NewsFeed - 19 Feb 2009
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Dec 2008
Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Aug 2008
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
Biopharmaceuticals
 HSMN NewsFeed - 5 Aug 2008
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 31 May 2008
Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 May 2008
Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
Devices Interventional
 HSMN NewsFeed - 31 Mar 2008
First Statin Monotherapy to Achieve Regression of Coronary Atherosclerosis by Angiography in a Major Clinical Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Jan 2008
First Head to Head Study Comparing Crestor(TM) and Lipitor(R) Effects on the Treatment of Atherosclerosis
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Nov 2007
Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 9 Nov 2007
CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
Biopharmaceuticals FDA Cardiology
 HSMN NewsFeed - 7 Nov 2007
New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Nov 2007
New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Aug 2007
Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Biopharmaceuticals
 HSMN NewsFeed - 25 Mar 2007
First Study to Show Positive Benefit on Atherosclerosis for People With Early Signs of Diseased Arteries
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 30 Jan 2007
Statins Can Slow Progression of Aortic Valve Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Jan 2007
Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 6 Nov 2006
Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Oct 2006
FDA Approves New Label for VYTORIN(R) (ezetimibe/simvastatin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Sep 2006
New EXPLORER Results Show Patients Achieved Dramatic Reductions in C-Reactive Protein And LDL-C Levels With CRESTOR Combination Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Jul 2006
Abbott and AstraZeneca Announce Collaboration to Develop and Commercialize CRESTOR(R) and Next-Generation TriCor(R) (ABT-335) Fixed-Dose Combination
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Jun 2006
New Data Shows CRESTOR(R) Helped African American, Hispanic American and South Asian American Patients Significantly Lower LDL-C and Achieve Cholesterol Goals
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 May 2006
CRESTOR Helped More Patients Reach Goal in MERCURY II Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 May 2006
Response Biomedical and Shionogi Finalize Commercialization Agreement For RAMP Cardiovascular Testing in Japan
Diagnostics Cardiology
Return to NewsFeed  

 Additional items found! 29

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 29 additional stories matching:
CRESTOR
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.